Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Odronextamab→

Odronextamab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1801338-64-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Bispecific monoclonal antibodyCD20×CD3 T-cell-engaging immunotherapy
Mechanism of action
Binds CD20 on B-lineage cells and CD3 on T cells, bringing T cells into close proximity with malignant B cells and promoting T-cell-mediated cytotoxicity against CD20-expressing cells.
Indications / reported uses
  • Investigational treatment studied in adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma; this is not a statement of a universal marketing authorisation.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/odronextamab

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Odronextamab Environmental Risk Assessment (ERA) (the Odronextamab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.